financetom
Business
financetom
/
Business
/
PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says
Aug 29, 2024 8:55 AM

12:17 PM EDT, 08/26/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) is positioned for potential upside with several key catalysts on the horizon, UBS said in a note Monday.

"With multiple [New Drug Application] filings this year & potential commercial launches next year (PKU, FA, AADC) along with upcoming clinical catalysts [HD data and ALS Phase 2 results in Q4), we see upside potential for shares," UBS said.

The Committee for Medicinal Products for Human Use of the European Medical Agency has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy in June.

PTC is seeking marketing authorization from the European Medicines Agency for sepiapterin as a treatment for phenylketonuria, or PKU, a rare metabolic disease that affects the brain.

The company said last month the application for European marketing authorization for sepiapterin is under review while marketing authorization applications for Japan and Brazil are anticipated to be filed later this year.

UBS said that while Translarna's recent removal from the European market has overshadowed PTC Therapeutics' ( PTCT ) pipeline, it sees an "upside" in the potential approval/launch of PKU treatment next year.

The brokerage said it estimates unadjusted peak sales of $1.3 billion for metabolic disorder treatment sepiapterin due to its oral administration advantage and broader eligible age range.

The US Food and Drug Administration in May granted priority review for its biologics license application for gene therapy Upstaza, a one-time gene replacement therapy for aromatic L-amino acid decarboxylase, or AADC, deficiency in patients 18 months and older.

Upcoming decisions on AADC and FA, as well as potential regulatory feedback on HD, further enhance PTC Therapeutics' ( PTCT ) outlook, UBS said.

UBS said it resumed PTC Therapeutics ( PTCT ) coverage with a buy rating and a $47 price target.

Shares of the company rose more than 1% in recent trading.

Price: 34.58, Change: +0.43, Percent Change: +1.26

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Shell Unveils New Strategy: Higher Buybacks, Cost Cuts And 10% Annual Free Cash Flow Growth
Shell Unveils New Strategy: Higher Buybacks, Cost Cuts And 10% Annual Free Cash Flow Growth
Mar 25, 2025
On Tuesday, at Capital Markets Day 2025, Shell PLC ( SHEL ) disclosed several strategic updates and investments. The company plans to increase shareholder distributions from 30%-40% to 40%-50% of cash flow from operations (CFFO) throughout economic cycles. In particular, the company expects to focus on share buybacks while maintaining a 4% annual progressive dividend policy. Shell plans to prioritize...
Market Chatter: Tesla's Market Share in Europe Declines in February
Market Chatter: Tesla's Market Share in Europe Declines in February
Mar 25, 2025
06:48 AM EDT, 03/25/2025 (MT Newswires) -- Tesla's (TSLA) market share in Europe decreased year-over-year in February, Reuters reported Tuesday citing data from the European Automobile Manufacturers Association. Sales for the electric car maker fell for a second month amid increased competition and a slowdown in European economies. Despite a rise in overall EV registrations on the continent, data showed...
Chile's Central Bank Upholds Cautious Game Plan, Says Deutsche Bank
Chile's Central Bank Upholds Cautious Game Plan, Says Deutsche Bank
Mar 25, 2025
06:42 AM EDT, 03/25/2025 (MT Newswires) -- The Chilean Central Bank (BCCh) decided by unanimity to leave the policy rate steady at 5%, in line with Deutsche Bank's consensus-matching expectation. The bank read the policy statement as striking a slight hawkish tone. On the external front, the BCCh noted the substantial surge of uncertainty stemming from geopolitical developments, import tariffs...
DeepSeek Rolls Out Upgraded V3-0324 Model
DeepSeek Rolls Out Upgraded V3-0324 Model
Mar 25, 2025
06:39 AM EDT, 03/25/2025 (MT Newswires) -- Chinese artificial intelligence startup DeepSeek has rolled out DeepSeek-V3-0324, an upgrade to its V3 large language model, according to a post on artificial intelligence development platform Hugging Face's website Tuesday. The announcement added that the new model has notable improvements over the previous model in several key areas, including enhanced benchmark performance, front-end...
Copyright 2023-2025 - www.financetom.com All Rights Reserved